CY1120304T1 - Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας - Google Patents

Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας

Info

Publication number
CY1120304T1
CY1120304T1 CY20171100460T CY171100460T CY1120304T1 CY 1120304 T1 CY1120304 T1 CY 1120304T1 CY 20171100460 T CY20171100460 T CY 20171100460T CY 171100460 T CY171100460 T CY 171100460T CY 1120304 T1 CY1120304 T1 CY 1120304T1
Authority
CY
Cyprus
Prior art keywords
activity
methods
microrna
mir
units
Prior art date
Application number
CY20171100460T
Other languages
English (en)
Inventor
Balkrishen Bhat
Original Assignee
Regulus Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc. filed Critical Regulus Therapeutics Inc.
Publication of CY1120304T1 publication Critical patent/CY1120304T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Abstract

Στο κείμενο περιγράφονται συνθέσεις και μέθοδοι για την αναστολή της -21 δραστικότητας. Οι συνθέσεις έχουν συγκεκριμένα περιγράμματα τροποποίησης νουκλεοζιτών που παρέχουν ισχυρούς αναστολείς της -21 δραστικότητας. Οι συνθέσεις είναι δυνατό να χρησιμοποιηθούν για την αναστολή του -21, και επίσης για την αγωγή παθήσεων συνδεόμενων με παθολογική έκφραση του -21, όπως ίνωσης και καρκίνου.
CY20171100460T 2011-04-25 2017-04-25 Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας CY1120304T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US201161565779P 2011-12-01 2011-12-01
PCT/US2012/034880 WO2012148952A1 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Publications (1)

Publication Number Publication Date
CY1120304T1 true CY1120304T1 (el) 2019-07-10

Family

ID=46025979

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100460T CY1120304T1 (el) 2011-04-25 2017-04-25 Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας

Country Status (30)

Country Link
US (7) US20120270928A1 (el)
EP (3) EP3933040A1 (el)
JP (2) JP6320292B2 (el)
KR (2) KR102055172B1 (el)
CN (3) CN113249381A (el)
AU (4) AU2012249851B2 (el)
BR (1) BR112013027187A2 (el)
CA (2) CA3165397A1 (el)
CL (1) CL2013003105A1 (el)
CO (1) CO6821889A2 (el)
CY (1) CY1120304T1 (el)
DK (2) DK2702155T3 (el)
EA (1) EA025894B1 (el)
ES (2) ES2868950T3 (el)
HK (1) HK1243130A1 (el)
HR (2) HRP20170557T2 (el)
HU (2) HUE031595T2 (el)
IL (3) IL229032B (el)
LT (2) LT3211082T (el)
MX (5) MX2013012452A (el)
MY (2) MY175336A (el)
NZ (1) NZ717921A (el)
PL (2) PL3211082T3 (el)
PT (2) PT2702155T (el)
RS (1) RS61775B1 (el)
SG (1) SG194636A1 (el)
SI (2) SI2702155T1 (el)
TW (2) TWI698445B (el)
UA (1) UA115652C2 (el)
WO (1) WO2012148952A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2302055T3 (da) 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
CN113249381A (zh) 2011-04-25 2021-08-13 赛诺菲 用于调节mir-21活性的微rna化合物以及方法
WO2013153082A1 (en) * 2012-04-10 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of nonalcoholic steatohepatitis
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US20150291958A1 (en) 2012-11-15 2015-10-15 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
TW201446791A (zh) * 2013-05-01 2014-12-16 Regulus Therapeutics Inc 用於調節mir-122之微小rna化合物及方法
WO2015061536A1 (en) * 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
CA2935426C (en) * 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN111386351A (zh) 2017-09-22 2020-07-07 华盛顿大学 细胞分子的原位组合标记
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备***癌骨转移的诊断、预后试剂盒及药物中的应用
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP2428571B1 (en) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
ES2382807T3 (es) 2003-08-28 2012-06-13 Takeshi Imanishi Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
DK2302055T3 (da) 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
EP1959012A3 (en) 2004-12-29 2009-12-30 Exiqon A/S Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
EP1931780B1 (en) * 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense compounds having enhanced anti-microrna activity
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
KR20130042043A (ko) 2006-01-27 2013-04-25 아이시스 파마수티컬즈 인코포레이티드 6-변형된 바이시클릭 핵산 유사체
DK2666859T3 (en) * 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
CN102851291B (zh) * 2006-04-03 2016-03-09 斯特拉有限责任公司 包含抗微小rna反义寡核苷酸的药物组合物
DK2068886T3 (da) 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipidholdige præparater
WO2008043521A2 (de) 2006-10-09 2008-04-17 Julius-Maximilians-Universität Würzburg Microrna (mirna) zur diagnose und therapie von herzerkrankungen
CA2671294A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
EP2118118B1 (en) 2007-01-19 2017-09-27 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
ES2463665T3 (es) * 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
CA2704043C (en) * 2007-10-29 2018-09-18 Rosetta Genomics Ltd. Targeting micrornas for the treatment of liver cancer
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
CN102549166A (zh) * 2009-02-26 2012-07-04 俄亥俄州立大学研究基金会 从未吸烟者中的MicroRNA及相关材料和方法
NZ597078A (en) 2009-06-08 2013-11-29 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
CN113249381A (zh) 2011-04-25 2021-08-13 赛诺菲 用于调节mir-21活性的微rna化合物以及方法
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
WO2013192576A2 (en) 2012-06-21 2013-12-27 Miragen Therapeutics Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CA2886116C (en) 2012-09-26 2022-06-07 Mirrx Therapeutics Oligomers with improved off-target profile
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
TW201300404A (zh) 2013-01-01
CL2013003105A1 (es) 2014-08-01
HRP20210616T1 (hr) 2021-05-28
US20160138016A1 (en) 2016-05-19
DK3211082T3 (da) 2021-05-10
PL2702155T3 (pl) 2017-09-29
US20140107183A1 (en) 2014-04-17
HUE031595T2 (en) 2017-07-28
AU2017219156A1 (en) 2017-09-21
UA115652C2 (uk) 2017-12-11
MX2019003089A (es) 2019-07-18
EP2702155B9 (en) 2020-01-01
CA2833615C (en) 2022-08-30
JP2014518619A (ja) 2014-08-07
EP2702155B1 (en) 2017-02-01
PT2702155T (pt) 2017-04-03
TWI607016B (zh) 2017-12-01
EA201391492A1 (ru) 2014-04-30
US20220098583A1 (en) 2022-03-31
AU2017219156B2 (en) 2020-01-02
EP3933040A1 (en) 2022-01-05
JP2018121646A (ja) 2018-08-09
US20200291400A1 (en) 2020-09-17
RS61775B1 (sr) 2021-05-31
SI2702155T1 (sl) 2017-07-31
DK2702155T3 (en) 2017-05-01
AU2022203067A1 (en) 2022-05-26
TWI698445B (zh) 2020-07-11
TW201811812A (zh) 2018-04-01
MX2019003090A (es) 2019-07-18
CN103620035B (zh) 2021-04-23
US9790496B2 (en) 2017-10-17
LT3211082T (lt) 2021-05-10
AU2012249851A1 (en) 2013-10-31
NZ717921A (en) 2017-09-29
HK1243130A1 (zh) 2018-07-06
SI3211082T1 (sl) 2021-08-31
PT3211082T (pt) 2021-04-28
HUE054129T2 (hu) 2021-08-30
WO2012148952A1 (en) 2012-11-01
IL273381A (en) 2020-05-31
US9181547B2 (en) 2015-11-10
AU2012249851A8 (en) 2013-11-14
AU2020201403A1 (en) 2020-03-12
EP2702155A1 (en) 2014-03-05
MY187685A (en) 2021-10-11
KR20140033062A (ko) 2014-03-17
MY175336A (en) 2020-06-19
EA025894B1 (ru) 2017-02-28
CA2833615A1 (en) 2012-11-01
CN103620035A (zh) 2014-03-05
MX2022000212A (es) 2022-04-01
CN113151272A (zh) 2021-07-23
SG194636A1 (en) 2013-12-30
PL3211082T3 (pl) 2021-08-02
CN113249381A (zh) 2021-08-13
CO6821889A2 (es) 2013-12-31
ES2868950T3 (es) 2021-10-22
IL229032B (en) 2021-01-31
NZ616748A (en) 2016-03-31
EP3211082B1 (en) 2021-02-17
IL229032A0 (en) 2013-12-31
HRP20170557T1 (hr) 2017-06-16
US20140329887A1 (en) 2014-11-06
CA3165397A1 (en) 2012-11-01
KR102055172B1 (ko) 2020-01-23
ES2621863T9 (es) 2020-02-13
MX2013012452A (es) 2014-11-21
JP6320292B2 (ja) 2018-05-09
IL266529A (en) 2019-07-31
MX2022006595A (es) 2022-07-01
ES2621863T3 (es) 2017-07-05
AU2012249851B2 (en) 2017-06-08
US8912161B2 (en) 2014-12-16
BR112013027187A2 (pt) 2017-06-06
KR20190063482A (ko) 2019-06-07
LT2702155T (lt) 2017-05-10
US20180155719A1 (en) 2018-06-07
EP3211082A1 (en) 2017-08-30
US20120270928A1 (en) 2012-10-25
HRP20170557T2 (hr) 2020-02-21

Similar Documents

Publication Publication Date Title
CY1120304T1 (el) Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
PH12014502387A1 (en) Microrna compounds and methods for modulating mir-21 activity
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
CY1118740T1 (el) Ενωσεις αναστολης δραστικοτητας της ο-μεθυλτρανσφερασης κατεχολης
MX2019012252A (es) Composiciones y metodos para inhibir la expresion del gen alas1.
MX2016001037A (es) Inhibidores de factores de transcripción y usos.
MX2014003979A (es) Nucleosidos, nucleotidos, y acidos nucleicos modificados, y usos de los mismos.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2021010716A (es) Composiciones y metodos para inhibir la expresion del gen lect2.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
MY193444A (en) Cell-free production of ribonucleic acid
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
BR112017012134A2 (pt) prevenção e tratamento de condições inflamatórias
ECSP16005630A (es) Derivados de dehidroleucodina y usos de estos
BR112015019445A2 (pt) método para realizar uma construção têxtil de proteção balística, construção têxtil de proteção balística feita por um método e produto de proteção balística
TN2014000401A1 (en) Microrna compounds and methods for modulating mir-21 activity
UA94718U (uk) Застосування комбінації глюкозаміну гідрохлориду і n-ацетилглюкозаміну з кверцетином для корекції гематотоксичної та імунодепресивної дії алкілуючих протипухлинних засобів
BR112017024941A2 (pt) amidas heterocíclicas como inibidores de cinase
FI10126U1 (fi) Sovitelma tasomaisten tuotteiden, kuten teräslevyjen, tukemiseksi ja kuljettamiseksi
TH1401003558A (th) อนุพันธ์นิวคลีโอไซด์ที่ถูกแทนที่แบบ 4'-อะซิโด,3'-ฟลูออโรในฐานะที่เป็นตัวยับยั้งการถ่ายแบบ rna ของ hcv